Skip to content
Screener

EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.68B+68.1%
Amgen logo
AmgenAMGN
$4.63B+15.7%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$124.99M-119%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$41.02M+12.6%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$57.18M+24.5%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
-$26.2M-18.2%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$777.69M+597%
Enterprise value$769.81M+761%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Calculated from Climb Bio, Inc.’s reported figures.

$15.2Mebit+
$38.0KDepreciation Depletion & Amortization
=-$15.17M

The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026. Open the filing →

Filed
May 7, 2026, 7:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-210357

FAQ

What is Climb Bio, Inc.'s EBITDA?
Climb Bio, Inc. (CLYM) reported EBITDA of -$15.17M in Q1 2026.
How has Climb Bio, Inc.'s EBITDA changed year-over-year?
Climb Bio, Inc.'s EBITDA increased by 34.1% year-over-year, from -$23.02M to -$15.17M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Climb Bio, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude